Adult Dosing

Reduction of elevated IOP

• Instill 1-2 gtt in eye(s) qd-tid

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Reduction of elevated intraocular pressure

• Hypersensitivity to any of the ingredients of the product
• Acute iritis

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Risk for systemic toxicity and ocular toxicities exists
• On occurrence of sensitivity or if original irritation persists, discontinue the drug
• Geriatrics and patients with lens opacities are prone to possible spasm of accommodation and poor vision in dim light
• Elevation of IOP and precipitation of acute attacks have occurred in some patients with angle-closure glaucoma receiving miotics
• Possible lens opacities and cataracts have developed; regression of lens opacities have occurred on early discontinuation of therapy
• Conduct slit-lamp examinations regularly
• Temporarily discontinue therapy on occurrence of iris cysts, iritis, synechiae, or lens opacities

Cautions: Use cautiously in

• Acute cardiac failure
• Recent MI
• Hypertension
• Hypotension
• Bronchial asthma
• Peptic ulcer disease
• Hyperthyroidism
• GI spasm
• Urinary tract obstruction
• Parkinson's disease
• Corneal abrasion

Pregnancy Category:C

Breastfeeding: Literatures are unavailable on the use of carbachol ophthalmic drops during breastfeeding. As it posses short half-life, it is unlikely to reach the bloodstream of the infant and induce any adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 2 March 2011). Manufacturer advises caution.

• EENT: Ocular burning, ocular stinging, retinal detachment, blurred vision, ocular discomfort
• CV: Arrhythmias, hypotension
• RESP: Asthma

• Parasympathomimetic; precise mechanism of action is unknown; stimulates both muscarinic and nicotinic receptors, produces constriction of the iris and ciliary body and results in reduction of intraocular pressure
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Isopto Carbachol (Discontinued)

US Availability

Isopto Carbachol

• OPTH SOLN: 1.5%
• OPTH SOLN: 3%

Canadian Trade Name(s)

• Isopto Carbachol

Canadian Availability

Isopto Carbachol

• OPTH SOLN: 1.5%
• OPTH SOLN: 3%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Isopto Carbachol

Australian Availability

Isopto Carbachol

• OPTH SOLN: 1.5%
• OPTH SOLN: 3%

[Outline]

Ophthalmic

Ophthalmic Glaucoma Agents

Pricing data from www.DrugStore.com in U.S.A.

• Isopto Carbachol 1.5 % SOLN [Bottle] (ALCON VISION)
  15 % = $65.93
  45 % = $186.99
• Isopto Carbachol 3 % SOLN [Bottle] (ALCON VISION)
  15 % = $71.51
  45 % = $198.03

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.